Oxidative stress and inflammation in heart failure: Mechanisms of damage and therapeutic alternatives;Estrés oxidativo e inflamación en insuficiencia cardiaca: Mecanismos de daño y alternativas terapéuticas

Revista Medica de Chile

Volumn 135, Issue 8, 2007, Pages 1056-1063

  Miranda H, Rodrigo ^a   Castro G, Pablo ^a,d   Verdejo P, Hugo ^a   Chiong, Mario ^b   Díaz Araya, Guillermo ^b   Mellado, Rosemarie ^b   Rojas, Diego ^b   Concepción, Roberto ^c   Lavandero, Sergio ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c HOSPITAL DIPRECA   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Endothelial cells; Heart failure, congestive; Oxidative stress

Indexed keywords

METALLOPROTEINASE;

ANIMAL; DISEASE MODEL; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; INFLAMMATION; METALLOPROTEASES; OXIDATIVE STRESS;

EID: 36248987146     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. GRIEVE DJ, SHAH AM. Oxidative stress in heart failure. More than just damage. Eur Heart J 2003; 24: 2161-216.
2. PACHER P, SCHULZ R, LIAUDET L, SZABO C. Nitrosative stress and pharmacological modulation of heart failure. TRENDS Pharmacol Sciences 2005; 26: 165-76.
3. KENNETH E, LÓPEZ J, BUCKLER K, ARCHER S. Acute Oxygen-Sensing Mechanisms. N Engl J Med 2005; 353: 2042-55.
4. CASTRO P, DÍAZ G, NETTLE D, CORBALÁN R, PÉREZ O, LAVANDERO S ET AL. Effects of Early Decrease in Oxidative Stress After Medical Therapy in Patients With Class IV Congestive Heart Failure. Am J Cardiol 2002; 89: 243-54.
5. GONZÁLEZ A, FORTUNO MA, QUEREJETA R, RAVASSA S, LÓPEZ B, LÓPEZ N. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 2003; 59: 549-62.
6. FLORA SAM, DAVID L, PIMENTAL R, MULUKUTLA S, TABAEE A, BRISTOW R ET AL. Increased Reactive Oxygen Species Production and Functional Alterations in Antioxidant Enzymes in Human Failing Myocardium. Congest Heart Fail 2005; 11: 2130-44.
7. CASTRO P, GREIG D, PÉREZ O, CHIONG M, DÍAZ G, VUKASOVIC JL ET AL. Relation Between Oxidative Stress, Catecholamines, and Impaired Chronotropic Response to Exercise in Patients With Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. Am J Cardiol 2003; 92: 215-8.
8. POLI G, LEONARDUZZI G, BIASI F, CHIARPOTTO E. Oxidative stress and cell signalling. Curr Med Chem 2004; 11: 1163-82.
9. KAMEDA K, MATSUNAGA T, ABE N, HANADA H. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003; 24: 2180-5.
10. FINKEL T. Signal transduction by oxidative reactive species in non-phagocytic cells. J Leukocyte Biol 1999; 65: 337-40.
11. GRIENDLING KK, SORESCU D, USHIO M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
12. LANDMESSER U, SPIEKERMANN S, DIKALOV S, TATGE H, WILKE R, KOHLER C ET AL. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073-8.
13. PÉREZ O, CASTRO P, DÍAZ G, NETTLE D, MORAGA F, CHIONG M ET AL. Persistencia del estrés oxidativo postrasplante cardiaco: estudio comparativo entre pacientes con trasplante cardiaco y con insuficiencia cardiaca crónica estable. Rev Esp Cardiol 2002; 55: 831-7.
14. PAULUS WJ. Cytokines and heart failure. Heart Fail Monit 2000; 1: 50-6.
15. ABRAMS J. C-reactive protein, inflammation, and coronary risk: an update. Cardiol Clin 2003; 21: 327-31.
16. NOUTSIAS M, SEEBERG B, SCHULTHEISS H-P. Expression of cell adhesion molecules in dilated cardiomyopathy. Circulation 1999; 99: 2124-31.
17. AMMAR FZ, GANNON PO, AMIRI F, SCHIFFRIN E. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 2002; 39: 679-84.
18. JALIL JE, DOERING CW, JANICKI JS, PICK R, SHROFF SG, WEBER KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1999; 64: 1041-50.
19. THAIK CM, CALDERONE A, TAKAHASHI N, COLUCCI WS. Interleukin-1 modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96: 1093-9.
20. SATOH S, OYAMA J, SUEMATSU N, KADOKAMI T. Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. Inter J Cardiol 2005; 26: 1298-304.
21. DESSWAL A, PETERSEN NJ, FELDMAN AM, YOUNG JB, WHITE BB, MANN DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
22. ANKER SD, VOLTERRANI M, EGERER KR, FELTON CV, KOX WJ, POOLE PA, COATS AJ. Tumor necrosis factor as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM 1998; 91: 199-203.
23. SHARMA R, DAVIDOFF MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002; 8: 165-72.
24. LALU MM. Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Fail Rev 2002; 7: 359-69.
25. VISSE R, NAGASE H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
26. STERNLICHT MDL, WERB Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
27. SPINALE FG, COKER ML, HEUNG LJ, BOND BR. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-9.
28. TSURUDA T, COSTELLO LC, BURNETT JC. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004; 9: 53-61.
29. ALTIERI P, BRUNELLI S, GARIBALDI S, NICOLINO A, UBALDI S, SPALLAROSSA L ET AL. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-56.
30. LINKE A, ADAMS V, CHRISTIAN P, ERBS S, GIELEN S. Antioxidative Effects of Exercise Training in Patients With Chronic Heart Failure: Increase in Radical Scavenger Enzyme Activity in Skeletal Muscle. Circulation 2005; 111: 1763-70.
31. BERRY CE, HERE JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004; 555: 589-606.
32. CASTRO P, VUKASOVIC JL, CHIONG M, DÍAZ G, ALCAÍNO H, COPAJA M ET AL. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 1033-9.
33. GAVIN AD, STRUTHERS AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin and impairs ventricular function but does not alter exercise capacity in chronic heart failure. Heart 2005; 91: 749-53.
34. NAKAGAMI H, JENSEN KS, LIAO JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003; 35: 398-403.
35. FOLKERINGA RJ, VAN KRAAIJ DJ, TIELEMAN RG, NIEMAN FH, PINTO YM, CRIJNS HJ. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 2006; 12: 134-8.
36. WOJNICZ R, WILCZEK K, NOWALANY E, SZYGULA B, NOWAK J ET AL. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97: 899-904.
37. SRIKANTH S, MUHAMMAD Q, STAMATIOS L, NEERAJ T. Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure. JACC 2006; 47: 332-7.
38. TAVAZZI L, TOGNONI G, FRANZOSI MG, LATINI R, MAGGIONI AP, MARCHIOLI R. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 531-3.
39. PACHER P, MORRIS O, CLAUDE R. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12: 267-75.
40. CAMPT TM, BRAUN JC, POLLAK D, GAVIN L. Doxycycline ameliorates ischemic and borderzone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 2004; 23: 729-36.